Increased circulating CXCL13 levels in systemic lupus erythematosus and rheumatoid arthritis: a meta-analysis.
Yu-Qing BaoJun-Ping WangZi-Wei DaiYan-Mei MaoJun WuHeng-Sheng GuoYuan-Rui XiaDong-Qing YePublished in: Clinical rheumatology (2019)
This meta-analysis demonstrated increased circulating CXCL13 concentrations in SLE and RA patients. Circulating CXCL13 levels may act as biomarkers and therapy targets in the diagnosis and treatment of SLE and RA.Key Point• First, CXC ligand 13 (CXCL13) is closely related to the pathogenesis of systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), Second, this study may provide novel therapeutic targets for the treatment of SLE and RA patients. This meta-analysis provides a comprehensive analysis of circulating CXCL13 levels in patients with SLE and RA and also explores related influencing factors.
Keyphrases
- disease activity
- systemic lupus erythematosus
- rheumatoid arthritis
- ankylosing spondylitis
- systematic review
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- interstitial lung disease
- stem cells
- randomized controlled trial
- prognostic factors
- meta analyses
- systemic sclerosis
- bone marrow
- patient reported